Displaying drugs 4901 - 4925 of 10358 in total
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been …
STF-31
Experimental
SM-337
Investigational
SEL-24
Investigational
ST-003
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Investigational
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
Polaprezinc
Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. It was determined that polaprezinc may be effective in pressure ulcer treatment . A study in 2013 showed...
Experimental
Matched Description: … Polaprezinc is a chelated form of zinc and L-carnosine. ... A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine …
5-Mercaptoethanol-2-decenoyl-coenzyme A
Experimental
Sus scrofa placenta
Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
SQ-109
SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Investigational
Matched Description: … SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. …
V-SARS
COVID-19 convalescent plasma is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. Immunitor Inc., the sponsor, is currently testing this oral...
Investigational
Matched Description: … This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, …
SP-420
SP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).
Investigational
SP-101
Investigational
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected ... Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages …
ST-101
ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.
Investigational
Matched Description: … ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ... ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease. …
Strontium cation Sr-89
Experimental
SOT-107
SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour. About half of all brain tumours are gliomas.
Investigational
Matched Description: … About half of all brain tumours are gliomas. ... This drug treat for a type of brain cancer called a high grade glioma brain tumour. ... SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria …
SNS-314
SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. SNS-314 inhibits tumor growth in a variety of preclinical models, and...
Investigational
Matched Description: … SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. ... 314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of ... SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single …
SLV-334
SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.).
Investigational
SRX-246
Investigational
SYD-003
Investigational
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
SCIB1
SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.
Investigational
Matched Description: … It is being investigated for the treatment of melanoma. ... It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate …
SLC-391
Investigational
Displaying drugs 4901 - 4925 of 10358 in total